Wall Street Journal Examines Drugmakers' Use Of 'Unbranded Product Advertising' To Promote Disease Awareness, Treatment Options The Wall Street Journal on Friday examined "unbranded product advertising" for brand-name
drugs, which allow drugmakers to drive television viewers to Web sites promoting
drugs without the requirement of listing the products' side effects in the TV advertisement. FDA rules state that if an advertisement does not name a drug directly, it does not need to include a listing of possible side effects.
Source: www.medicalnewstoday.comCourt In Denmark Upholds Two Lipitor Patents, Prevents Launch Of Ranbaxy Generic Product Before November 2011 Pfizer Inc said that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company's favor in challenges to two of its patents covering atorvastatin, the active ingredient in Lipitor. The basic (DK 171,588) and enantiomer (EP 409,281) patents were challenged by generics manufacturer Ranbaxy. The court ruled that the basic patent, which expires in November 2011, would be infringed by Ranbaxy's generic atorvastatin product.
Source: www.medicalnewstoday.comImpending Generic Competition Forces Innovation In Alzheimer's Treatments As the Baby Boomer generation reaches retirement age, the number of Americans suffering from Alzheimer's disease is expected to jump from 5 million to about 14 million in 2050.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
